ANDA 75871, held by Chartwell Rx. Alendronate Sodium.
As of Nov 16, 2026, ANDA 75871 (Alendronate Sodium), held by Chartwell Rx, was first approved by FDA on Apr 22, 2009, with 3 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 22, 2009 | Original application | Approved | None posted |
| Alendronate SodiumEQ 5MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 10MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 40MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 35MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Alendronate SodiumEQ 70MG BASE · tablet;oral | Alendronate Sodium | Discontinued |
| Feb 25, 2016 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 25, 2016 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jan 20, 2015 | Supplement 1Labeling | Approved | None posted |
| Apr 22, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters